Florida Administrative Code › 61 - DEPARTMENT OF BUSINESS AND PROFESSIONAL REGULATION › 61DER - Division of Pari-Mutuel Wagering › Chapter 61DER21 - EMERGENCY RULE FOR YEAR 2021 › Section 61DER21-2 - Testing Methodologies; Measurement Uncertainties; Screening Limits

Current through Reg. 50, No. 138; July 16, 2024
In addition to the rules that exist under Rule
				  61D-6.008,
				  Florida Administrative Code, the following procedures are promulgated on an
				  emergency basis:
(1) Testing
				Methodologies: Methodologies used to screen for and confirm the administration
				of medications, drugs, and naturally occurring substances in horses shall be
				limited to the following: Immunoassay, Liquid Chromatography Mass Spectrometry
				(LCMS), Gas Chromatography Mass Spectrometry (GCMS), and/or Specific
				Gravity.
(2) Measurement
				Uncertainties: The established levels utilized by the division laboratory are
				as follows:
SUBSTANCE
MEASUREMENT UNCERTAINTY
(a) acepromazine [2-(1-hydroxyethyl) promazine
							 sulfoxide]
(b) albuterol
(c) betamethasone
(d) butorphanol
(e) clenbuterol
(f) dantrolene (5-hydroxydantrolene)
(g) detomidine (carboxydetomidine)
(h) dexamethasone
(i) diclofenac
(j) dimethyl sulfoxide (DMSO)
(k) firocoxib
(l) furosemide
(m) glycopyrrolate
(n) isoflupredone
(o) lidocaine (OH-lidocaine)
(p) mepivacaine (hydroxymepivacaine)
(q) methocarbamol
(r) methylprednisolone
(s) omeprazole
(t) prednisolone
(u) procaine penicillin
(v) triamcinolone acetonide
(w) xylazine
(x) ketoprofen
(z) phenylbutazone
(aa) flunixin
(ab) boldenone
(ac) testosterone
(ad) nandrolone
							 (5[ALPHA]-oestrane-3[BETA],17[ALPHA]-diol)
(ae) stanozolol, 16[BETA]-hydroxystanozolol
No greater than +/- 1 ng/ml (urine)
No greater than +/- 0.05 ng/ml (urine)
No greater than +/- 6 pg/ml (serum)
No greater than +/- 0.4 ng/ml (serum)
No greater than +/- 30 pg/ml (urine)
No greater than +/- 3.2 pg/ml (serum)
No greater than +/- 12 pg/ml (serum)
No greater than +/- 2.9 pg/ml (urine)
No greater than +/- 5 pg/ml (serum)
No greater than +/- 0.4 ng/ml (serum)
No greater than +/- 1 [MICRO]g/ml (serum)
No greater than +/- 2.1 ng/ml (serum)
No greater than +/- 4.4 ng/ml (serum)
No greater than +/- 0.6 pg/ml (serum)
No greater than +/- 27 pg/ml (serum)
No greater than +/- 1.8 pg/ml (serum)
No greater than +/- 1.5 ng/ml (urine)
No greater than +/- 0.05 ng/ml (serum)
No greater than +/- 16 pg/ml (serum)
No greater than +/- 0.09 ng/ml (urine)
No greater than +/- 0.2 ng/ml (serum)
No greater than +/- 10 ng/ml (serum)
No greater than +/- 20 pg/ml (serum)
No greater than +/- 1.6 pg/ml (serum)
No greater than +/- 0. 21 ng/ml (primary;
							 serum)
No greater than +/- 0.15 ng/ml (secondary;
							 serum)
No greater than +/- 0.3 [MICRO]g/ml (primary;
							 serum)
No greater than +/- 0.025 [MICRO]g/ml (secondary;
							 serum)
No greater than +/- 1.9 ng/ml (primary; serum)
No greater than +/- 0.13 ng/ml (secondary;
							 serum)
No greater than +/- 2.5 ng/ml (urine; male
							 horses)
No greater than +/- 11 ng/ml (urine)
No greater than +/- 2.2 ng/ml (urine; male
							 horses)
No greater than +/- 0.17 ng/ml (urine)
If a sample is diluted for testing, the measurement
				  uncertainty is multiplied by the factor of dilution.
(3) Screening Limit for Prohibited Substances
				in Horses: Any and all findings above zero that are over the limit of
				detection, under any condition of use, for prohibited substances shall be
				considered a violation of Section
				550.2415,
				F.S.
Rulemaking Authority 550.0251(3), (11) 550.2415 (12) FS.
					 Law Implemented 550.0251, 550.2415 FS.